

Isabel Santana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6278712/publications.pdf>

Version: 2024-02-01

199
papers

9,448
citations

44069

48
h-index

48315

88
g-index

210
all docs

210
docs citations

210
times ranked

13324
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
2	Montreal Cognitive Assessment. Alzheimer Disease and Associated Disorders, 2013, 27, 37-43.	1.3	356
3	Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. BMC Research Notes, 2011, 4, 299.	1.4	284
4	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
5	Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiology of Aging, 2004, 25, 105-110.	3.1	266
6	Mitochondria dysfunction of Alzheimer's disease cybrids enhances A β toxicity. Journal of Neurochemistry, 2004, 89, 1417-1426.	3.9	258
7	A Pan-European Study of the C9orf72 Repeat Associated with FTD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247
8	Montreal Cognitive Assessment (MoCA): Normative study for the Portuguese population. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 989-996.	1.3	242
9	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
10	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of Aging, 2010, 31, 725-731.	3.1	196
11	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
12	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
13	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	10.1	144
14	Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1428-1441.	3.8	137
15	Peripheral Inflammatory Cytokines as Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment. Neurodegenerative Diseases, 2007, 4, 406-412.	1.4	135
16	Peripheral Oxidative Damage in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 117-128.	2.6	133
17	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
18	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128

#	ARTICLE	IF	CITATIONS
19	Construct Validity of the Montreal Cognitive Assessment (MoCA). Journal of the International Neuropsychological Society, 2012, 18, 242-250.	1.8	124
20	Montreal Cognitive Assessment (MoCA): Validation Study for Vascular Dementia. Journal of the International Neuropsychological Society, 2012, 18, 1031-1040.	1.8	108
21	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	7.6	107
22	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
23	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
24	Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiology of Aging, 2016, 41, 200.e1-200.e5.	3.1	96
25	Montreal Cognitive Assessment: Influence of Sociodemographic and Health Variables. Archives of Clinical Neuropsychology, 2012, 27, 165-175.	0.5	93
26	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93
27	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
28	Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1008.e17-1008.e23.	3.1	86
29	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
30	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
31	Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. Journal of Neurology, 2010, 257, 728-734.	3.6	79
32	Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurology, 2006, 6, 24.	1.8	78
33	Oxidative Damage and Progression to Alzheimer's Disease in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 1165-1177.	2.6	78
34	Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 91.	6.2	78
35	Amyloid β -induced ER stress is enhanced under mitochondrial dysfunction conditions. Neurobiology of Aging, 2012, 33, 824.e5-824.e16.	3.1	72
36	Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines. Metabolic Brain Disease, 2014, 29, 563-568.	2.9	69

#	ARTICLE	IF	CITATIONS
37	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. <i>Nature Communications</i> , 2020, 11, 619.	12.8	67
38	Montreal Cognitive Assessment (MoCA): Validation study for Frontotemporal Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2012, 25, 146-154.	2.3	66
39	Addition of the A β 242/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 33.	6.2	63
40	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. <i>Alzheimer's and Dementia</i> , 2018, 14, 751-763.	0.8	61
41	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
42	The Relevance of Sociodemographic and Health Variables on MMSE Normative Data. <i>Applied Neuropsychology Adult</i> , 2015, 22, 311-319.	1.2	56
43	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.8	56
44	Comparison of Four Verbal Memory Tests for the Diagnosis and Predictive Value of Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 120-131.	1.3	55
45	Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1358-1366.	3.0	55
46	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	1.9	55
47	Retinal texture biomarkers may help to discriminate between Alzheimer's, Parkinson's, and healthy controls. <i>PLoS ONE</i> , 2019, 14, e0218826.	2.5	54
48	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017, 134, 475-487.	7.7	53
49	Genetic Variability in CLU and Its Association with Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e9510.	2.5	52
50	Differences between Early and Late-Onset Alzheimer's Disease in Neuropsychological Tests. <i>Frontiers in Neurology</i> , 2012, 3, 81.	2.4	51
51	MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 7-17.	2.4	51
52	The Free and Cued Selective Reminding Test Distinguishes Frontotemporal Dementia From Alzheimer's Disease. <i>Archives of Clinical Neuropsychology</i> , 2014, 29, 670-679.	0.5	50
53	Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. <i>Journal of Neurology</i> , 2009, 256, 1540-1550.	3.6	48
54	Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation. <i>Current Alzheimer Research</i> , 2012, 9, 881-889.	1.4	48

#	ARTICLE	IF	CITATIONS
55	The free and cued selective reminding test: Validation for mild cognitive impairment and Alzheimer's disease. <i>Journal of Neuropsychology</i> , 2015, 9, 242-257.	1.4	43
56	Disconnection as a mechanism for social cognition impairment in multiple sclerosis. <i>Neurology</i> , 2017, 89, 38-45.	1.1	43
57	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
58	Prognosis of Early-Onset vs. Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors. <i>Geriatrics (Switzerland)</i> , 2016, 1, 11.	1.7	38
59	Transthyretin stability is critical in assisting beta amyloid clearance—Relevance of transthyretin stabilization in Alzheimer's disease. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 605-619.	3.9	38
60	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 46, 235.e1-235.e9.	3.1	37
61	Psychometric Properties of the Montreal Cognitive Assessment (MoCA): An Analysis Using the Rasch Model. <i>Clinical Neuropsychologist</i> , 2014, 28, 65-83.	2.3	36
62	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
63	Serial position effects in Alzheimer's disease, mild cognitive impairment, and normal aging: Predictive value for conversion to dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 841-852.	1.3	35
64	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	3.1	34
65	The Montreal Cognitive Assessment (MoCA) as a screening test for cognitive dysfunction in multiple sclerosis. <i>Applied Neuropsychology Adult</i> , 2018, 25, 57-70.	1.2	34
66	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. <i>Alzheimer's and Dementia</i> , 2017, 13, 1013-1023.	0.8	33
67	Predicting progression of mild cognitive impairment to dementia using neuropsychological data: a supervised learning approach using time windows. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 110.	3.0	33
68	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
69	Impaired Processing of 3D Motion-Defined Faces in Mild Cognitive Impairment and Healthy Aging: An fMRI Study. <i>Cerebral Cortex</i> , 2013, 23, 2489-2499.	2.9	31
70	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
71	Novel progranulin mutation: Screening for PGRN mutations in a Portuguese series of FTD/CBS cases. <i>Movement Disorders</i> , 2008, 23, 1269-1273.	3.9	30
72	Premorbid IQ Influence on Screening Tests™ Scores in Healthy Patients and Patients With Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2013, 26, 117-126.	2.3	30

#	ARTICLE	IF	CITATIONS
73	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. <i>Brain</i> , 2023, 146, 321-336.	7.6	30
74	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	4.4	29
75	Progranulin Peripheral Levels as a Screening Tool for the Identification of Subjects with Progranulin Mutations in a Portuguese Cohort. <i>Neurodegenerative Diseases</i> , 2014, 13, 214-223.	1.4	28
76	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid- β Levels in Patients with Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 1069-1078.	2.6	28
77	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
78	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
79	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
80	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	5.2	27
81	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
82	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
83	Cerebrospinal fluid A β ⁴⁰ is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. <i>Journal of the Neurological Sciences</i> , 2015, 358, 308-316.	0.6	25
84	Adiponectin and sporadic Alzheimer's disease: Clinical and molecular links. <i>Frontiers in Neuroendocrinology</i> , 2019, 52, 1-11.	5.2	25
85	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	1.9	25
86	Theory of Mind and Executive Functions are Dissociated in Multiple Sclerosis. <i>Archives of Clinical Neuropsychology</i> , 2018, 33, 541-551.	0.5	24
87	Validation study of the Alzheimer's disease assessment scale's cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease. <i>Clinical Neuropsychologist</i> , 2018, 32, 46-59.	2.3	24
88	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. <i>Human Mutation</i> , 2015, 36, 1226-1235.	2.5	23
89	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	1.9	23
90	The Clock Drawing Test: Portuguese Norms, by Age and Education, for Three Different Scoring Systems. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 375-387.	0.5	22

#	ARTICLE	IF	CITATIONS
91	Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease. <i>Epilepsy and Behavior</i> , 2019, 98, 207-209.	1.7	22
92	Prediction of Long-Term (5 Years) Conversion to Dementia Using Neuropsychological Tests in a Memory Clinic Setting. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 681-689.	2.6	21
93	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <sc>NfL</sc> and <sc>pNfH</sc>: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
94	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 659-667.	1.9	21
95	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. <i>Molecular Neurobiology</i> , 2019, 56, 2811-2821.	4.0	20
96	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	3.3	20
97	Alzheimer's Disease Genetics: Review of Novel Loci Associated with Disease. <i>Current Genetic Medicine Reports</i> , 2020, 8, 1-16.	1.9	20
98	Estimates of Geriatric Delirium Frequency in Noncardiac Surgeries and Its Evaluation Across the Years: A Systematic Review and Meta-Analysis. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 613-620.e9.	2.5	20
99	Adaptive visual memory reorganization in right medial temporal lobe epilepsy. <i>Epilepsia</i> , 2008, 49, 1395-1408.	5.1	19
100	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 66, 181.e3-181.e10.	3.1	19
101	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 2.	6.2	19
102	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	5.3	19
103	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	2.7	19
104	Temporal Integration of 3D Coherent Motion Cues Defining Visual Objects of Unknown Orientation is Impaired in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 885-896.	2.6	18
105	The neural basis of fatigue in multiple sclerosis. <i>Neurology: Clinical Practice</i> , 2018, 8, 492-500.	1.6	18
106	Association between Adipokines and Biomarkers of Alzheimer's Disease: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 725-735.	2.6	18
107	C-reactive protein as a predictor of mild cognitive impairment conversion into Alzheimer's disease dementia. <i>Experimental Gerontology</i> , 2020, 138, 111004.	2.8	18
108	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18

#	ARTICLE	IF	CITATIONS
109	Multiple Dural Arteriovenous Fistulas Presenting as Rapidly Progressive Dementia. <i>Neurologist</i> , 2012, 18, 130-132.	0.7	17
110	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018, 62, 245.e1-245.e7.	3.1	16
111	CYLD variants in frontotemporal dementia associated with severe memory impairment in a Portuguese cohort. <i>Brain</i> , 2020, 143, e67-e67.	7.6	16
112	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. <i>Brain</i> , 2022, 145, 700-712.	7.6	16
113	The Portuguese version of Addenbrooke's Cognitive Examination-Revised (ACE-R) in the diagnosis of subcortical vascular dementia and Alzheimer's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2015, 22, 473-485.	1.3	15
114	Adenosine Deaminase Two and Immunoglobulin M Accurately Differentiate Adult Sneddon's Syndrome of Unknown Cause. <i>Cerebrovascular Diseases</i> , 2018, 46, 257-264.	1.7	15
115	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018, 69, 293.e9-293.e11.	3.1	15
116	Face-Specific Perceptual Distortions Reveal A View- and Orientation-Independent Face Template. <i>Current Biology</i> , 2020, 30, 4071-4077.e4.	3.9	15
117	The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence. <i>Biomedicines</i> , 2022, 10, 315.	3.2	15
118	Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2017, 641, 101-106.	2.1	14
119	Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia. <i>European Journal of Neurology</i> , 2022, 29, 36-46.	3.3	14
120	Scaling Cognitive Domains of the Montreal Cognitive Assessment: An Analysis Using the Partial Credit Model. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 435-447.	0.5	13
121	The free and cued selective reminding test for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: A prospective longitudinal study. <i>Journal of Neuropsychology</i> , 2017, 11, 40-55.	1.4	13
122	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	3.1	13
123	Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8680.	4.1	13
124	The Retinal Inner Plexiform Synaptic Layer Mirrors Grey Matter Thickness of Primary Visual Cortex with Increased Amyloid Load in Early Alzheimer's Disease. <i>Neural Plasticity</i> , 2020, 2020, 1-11.	2.2	13
125	Frontotemporal dementia and mitochondrial DNA transitions. <i>Neurobiology of Disease</i> , 2004, 15, 306-311.	4.4	12
126	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	3.1	12

#	ARTICLE	IF	CITATIONS
127	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	2.6	12
128	Validity and Clinical Utility of Different Clock Drawing Test Scoring Systems in Multiple Forms of Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2018, 31, 114-122.	2.3	12
129	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	1.9	12
130	Investigating the Spatial Associations Between Amyloid- β^2 Deposition, Grey Matter Volume, and Neuroinflammation in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 113-132.	2.6	12
131	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
132	Cognitive deficits in middle-aged and older adults with bipolar disorder and cognitive complaints: Comparison with mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 624-631.	2.7	11
133	Characterization of an FTL-D-PDB family with the coexistence of SQSTM1 mutation and hexanucleotide (G 4 C 2) repeat expansion in <i>C9orf72</i> gene. <i>Neurobiology of Aging</i> , 2016, 40, 191.e1-191.e8.	3.1	11
134	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of $A\beta^2$ species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	2.7	11
135	Interplay Between Macular Retinal Changes and White Matter Integrity in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 723-732.	2.6	11
136	Neuropsychological profile of amyloid-positive versus amyloid-negative amnesic Mild Cognitive Impairment. <i>Journal of Neuropsychology</i> , 2021, 15, 41-52.	1.4	11
137	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	2.6	10
138	The Influence of Adipose Tissue on Brain Development, Cognition, and Risk of Neurodegenerative Disorders. <i>Advances in Neurobiology</i> , 2017, 19, 151-161.	1.8	10
139	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S647-S657.	2.6	10
140	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 608-616.	1.9	10
141	Clock drawing test in mild cognitive impairment: Correlation with cerebral perfusion in single-photon emission computed tomography.. <i>Neuropsychology</i> , 2019, 33, 617-632.	1.3	10
142	Mitochondrial DNA Variants in a Portuguese Population of Patients with Alzheimer's Disease. <i>European Neurology</i> , 2005, 53, 121-124.	1.4	9
143	Free and Cued Selective Reminding Test is superior to the Wechsler Memory Scale in discriminating mild cognitive impairment from Alzheimer's disease. <i>Geriatrics and Gerontology International</i> , 2015, 15, 961-968.	1.5	9
144	Do MCI patients with vitamin B12 deficiency have distinctive cognitive deficits?. <i>BMC Research Notes</i> , 2013, 6, 357.	1.4	8

#	ARTICLE	IF	CITATIONS
145	Neuroimaging Correlates of Frontotemporal Dementia Associated with SQSTM1 Mutations. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 303-313.	2.6	8
146	Advanced MRI study of migrainous infarction presenting as cortical laminar necrosis – Case report and literature review. <i>Clinical Neurology and Neurosurgery</i> , 2018, 167, 82-85.	1.4	8
147	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. <i>Biomolecules</i> , 2019, 9, 800.	4.0	8
148	Toulouse-Pierson Cancellation Test: Normative scores for the portuguese population. <i>Applied Neuropsychology Adult</i> , 2023, 30, 169-175.	1.2	8
149	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
150	Selective Reminding and Free and Cued Selective Reminding in Mild Cognitive Impairment and Alzheimer Disease. <i>Applied Neuropsychology Adult</i> , 2016, 23, 85-93.	1.2	7
151	Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1097-1105.	2.6	7
152	Data-driven staging of genetic frontotemporal dementia using multi-modal MRI. <i>Human Brain Mapping</i> , 2022, 43, 1821-1835.	3.6	7
153	Prosopagnosia as the Presenting Symptom of Whipple Disease. <i>Cognitive and Behavioral Neurology</i> , 2016, 29, 100-106.	0.9	6
154	Three-Dimensional Face Recognition in Mild Cognitive Impairment: A Psychophysical and Structural MR Study. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 744-754.	1.8	6
155	The Head Turning Sign in Dementia and Mild Cognitive Impairment: Its Relationship to Cognition, Behavior, and Cerebrospinal Fluid Biomarkers. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 42-49.	1.5	6
156	A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β -amyloid ₄₂ , total-tau, phospho-tau and α -synuclein in the differential diagnosis of neurodegenerative dementia. <i>Journal of Neurology</i> , 2020, 267, 2567-2581.	3.6	6
157	Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 785-796.	2.6	6
158	Severe post-influenza (H1N1) encephalitis involving pulvinar nuclei in an adult patient: Figure 1. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212667.	0.5	6
159	TeLPI Performance in Subjects With Mild Cognitive Impairment and Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 324-329.	1.3	5
160	Discriminative capacity and construct validity of the Clock Drawing Test in Mild Cognitive Impairment and Alzheimer's disease. <i>Clinical Neuropsychologist</i> , 2019, 33, 1159-1174.	2.3	5
161	Single Word Repetition Predicts Long-Term Outcome of Aphasia Caused by an Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104566.	1.6	5
162	Early-onset phenotype of bi-allelic GRN mutations. <i>Brain</i> , 2021, 144, e22-e22.	7.6	5

#	ARTICLE	IF	CITATIONS
163	Combined Structural MR and Diffusion Tensor Imaging Classify the Presence of Alzheimer's Disease With the Same Performance as MR Combined With Amyloid Positron Emission Tomography: A Data Integration Approach. <i>Frontiers in Neuroscience</i> , 2021, 15, 638175.	2.8	5
164	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
165	Can Subjective Memory Complaints Identify A β Positive and A β Negative Amnesic Mild Cognitive Impairment Patients?. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 1103-1111.	2.6	4
166	Knowing how to do it or doing it? A double dissociation between tool-gesture production and tool-gesture knowledge. <i>Cortex</i> , 2021, 141, 449-464.	2.4	4
167	Biparietal variant of Alzheimer's disease: a rare presentation of a common disease. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207011-bcr2014207011.	0.5	4
168	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
169	Frontotemporal dementia: neuroanatomical correlates of an atypical presentation. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014205089-bcr2014205089.	0.5	3
170	Construct and diagnostic validities of the Free and Cued Selective Reminding Test in the Alzheimer's disease spectrum. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 913-924.	1.3	3
171	Lower CSF Amyloid-Beta1 β 42 Predicts a Higher Mortality Rate in Frontotemporal Dementia. <i>Diagnostics</i> , 2019, 9, 162.	2.6	3
172	Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype. <i>Brain Communications</i> , 2020, 2, fcaa126.	3.3	3
173	Neuropsychological features of progranulin-associated frontotemporal dementia: a nested case-control study. <i>Neural Regeneration Research</i> , 2021, 16, 910.	3.0	3
174	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
175	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
176	[P4 β 189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1337.	0.8	2
177	Using the Rasch analysis for the psychometric validation of the Irregular Word Reading Test (TelPI): A Portuguese test for the assessment of premorbid intelligence. <i>Clinical Neuropsychologist</i> , 2018, 32, 60-76.	2.3	2
178	PHACTR1 genetic variability is not critical in small vessel ischemic disease patients and Pcoma recruitment in C57BL/6J mice. <i>Scientific Reports</i> , 2021, 11, 6072.	3.3	2
179	The European Portuguese version of the Oxford Cognitive Screening (OCS-Pt): a screening test for acute stroke patients. <i>Neurological Sciences</i> , 2022, 43, 3717-3728.	1.9	2
180	Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 9.	6.2	2

#	ARTICLE	IF	CITATIONS
181	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
182	Lewy body dementia is associated with an increased risk of atrial fibrillation: A case-control study. <i>Journal of Clinical Neuroscience</i> , 2022, 99, 62-65.	1.5	2
183	Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	2
184	Sporadic Creutzfeldt-Jakob Disease Causing a 2-Years Slowly Progressive Isolated Dementia. <i>Behavioural Neurology</i> , 2009, 21, 175-179.	2.1	1
185	Genetic Variation of <i>MT-ND</i> Genes in Frontotemporal Lobar Degeneration: Biochemical Phenotype-Genotype Correlation. <i>Neurodegenerative Diseases</i> , 2015, 15, 70-80.	1.4	1
186	Clinical Reasoning: A 55-year-old man with rapidly progressive dementia and parkinsonism. <i>Neurology</i> , 2017, 89, e182-e187.	1.1	1
187	Protective effects of cognitive and brain reserve in multiple sclerosis: Differential roles on social cognition and "classic cognition". <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102716.	2.0	1
188	Outcomes on Social and Classic Cognition in adults with Pediatric-onset Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103071.	2.0	1
189	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 336-339.	1.9	1
190	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
191	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	3.6	1
192	The <i>CBLA</i> detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1
193	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
194	Cognitive Trajectories Following Acute Infection in Older Patients With and Without Cognitive Impairment: An 1-Year Follow-Up Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 754489.	2.6	1
195	[P3111]: NOVEL CANDIDATE GENES FOR DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P977.	0.8	0
196	P1280: CEREBROSPINAL FLUID A β 42 AND TAU MEASUREMENT ON LUMIPULSE $\text{\textcircled{R}}$ G: ANALYTICAL VERIFICATION AND METHOD COMPARISON. <i>Alzheimer's and Dementia</i> , 2018, 14, P390.	0.8	0
197	APOE ϵ 4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 587-601.	2.6	0
198	Incidental findings in peer neurological examination. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117065.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Cytogenomic Analysis of Long-Term Epilepsy-Associated Tumors Using an Array-Based CGH Strategy. Cytogenetic and Genome Research, 2022, 162, 28-33.	1.1	0